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Plasminogen activator inhibitor (PAI) purified from human epidermis [(1986) FEBS Lett. 408, 273-2771 was immuno- 
logically identified as placental-type PAI-2. In both fibrinolytic and synthetic substrate assays inhibitory activity of epider- 
ma1 PA1 was neutralized by anti-PAI-2, but not by anti-endothelial type PAI-1. Immunoblotting technique confirmed 
that the purified epidermal PA1 is reactive with anti-PAI-2, but not with anti-PAI-1. Consequently PA1 in human 
epidermis was demonstrable by immunohistochemical technique. 
Placental-type plasminogen activator inhibitor-2; Endothelial-type plasminogen activator inhibitor-l; Urokinase; 
Tissue-type plasminogen activator; (Human epidermis) 
1. INTRODUCTION 
Tissue-type [l] and urokinase-type plasminogen 
activators (PAS) [2], have been found in various 
tissues and body fluids [3-51. On the other hand, 
recent studies have demonstrated that PA activities 
are controlled by, at least, two classes of specific 
PA inhibitors (PAIs), endothelial-type PAI- 
[6-91 and placental-type PAI- [9- 121. Recently 
Hibino et al. [ 131 have purified PAI from cornified 
cells of human epidermis. The epidermal PAI, 
with A& 43000 and pI 5.2, inactivated both 
urokinase and tissue-type PAS but did not inhibit 
plasmin, thrombin, glandular kallikrein or trypsin. 
It was postulated that PA activity in the normal 
epidermis is under control of the epidermal PA1 
[ 13,141, while exceeding PA activity in the skin 
becomes pathogenic in acantholytic bulla forma- 
tion [15], abnormal keratinization [ 161, and cancer 
metastasis [171. The present study investigated im- 
munologic cross reactivity of epidermal PA1 using 
Correspondence address: S. Izaki, Department of Der- 
matology, Iwate Medical University School of Medicine, 19-1 
Uchimaru, Morioka, Iwate 020, Japan 
monospecific antibodies against PAI- and PAI-2. 
The results benefit investigators to apply im- 
munohistochemical technique to the skin. 
2. MATERIALS AND METHODS 
2.1. Purification of epidermal PAI 
Epidermal PA1 was purified from cornified cells scraped 
from the foot of healthy individuals as previously reported 1131 
with modifications. Briefly, human cornified cells were ex- 
tracted with 0.1 M Tris-HCl (pH 8.0) + 0.14 M NaCl. Superna- 
tant was fractionated by Sephacryl S-200 and DEAE Sepharose 
chromatography. Inhibitor fraction was then applied to 
hydroxyapatite HPHT (Bio-Rad) and FPLC anion-exchanger 
Mono Q (Pharmacia) chromatography at pH 7.2 and 8.0. 
2.2. Preparation of PAI-I and PAI- 
Since platelet PA1 belongs to endothelial-type PAI- [8,9], 
we extracted platelet PA1 for PAI-1. Platelet-rich plasma was 
obtained from 100 ml of blood containing l/l0 volume of 
3.8% sodium citrate by centrifugation at 250 x g for 15 min. 
Platelets were collected after centrifugation at 800 x g for 
15 min and washed 5 times in modified Tyrode’s buffer 1181. 
PAI- was extracted with 1.5 ml of 0.5% Triton X-100 for 1 h 
at 4°C [ 191. PAI- partially purified from human placentas was 
obtained from Green Cross Co., Ltd, Osaka, Japan. This was 
further purified by FPLC Mono Q chromatography at pH 8.0, 
twice. 
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2.3. Anti-PA&l and anti-PAI- antibodies 
Monoclonal anti-human PAI- antibody was prepared from 
mouse hybridoma cells as reported 191. Monospecific polyclonal 
anti-human PAI- antibody was prepared from goat sera im- 
munized with purified PAI- [ll]. 
2.4. Immunoblotting 
After SDS slab gel electrophoresis, proteins were transferred 
to a nitrocellulose sheet electrophoretically as described by 
Howe and Hershey [20] at 200 mA for 8 h. The nitrocellulose 
sheet, washed three times for 5 min each with 0.02 M sodium- 
phosphate buffer + 0.14 M NaCI, pH 7.4 (PBS) containing 
0.1% Triton X-100 (TPBS), was incubated with anti-PAI- or 
anti-PA13 IgG for 30 min at room temperature. After rinsing 
with TPBS three times for 5 min each, the sheet was incubated 
with biotinylated anti-mouse IgG or anti-goat IgG diluted 1: 50 
in TPBS for 30 min and washed with TPBS three times for 
5 min each, according to the avidin-biotin-peroxidase complex 
(ABC) method [21] using StrAvigen (BioGenex Laboratories, 
Dublin, USA). After reaction with ABC (1: 50 dilution) for 
30 min and washing with PBS the sheet was immersed in 
diaminobenzidine (5 mg/lO ml). Reaction was stopped by rins- 
ing with water. 
2.5. Inhibitor assays 
Calorimetric inhibitor assay for urokinase was done using 
Glu-Gly-Arg-p-nitroanilide (Kabi Diagnostica, Stockholm, 
Sweden) as substrate [13]. Urokinase (12 IU/O. 1 ml) (W 
55000; Green Cross, Tokyo, Japan) was mixed with 0.05 ml of 
sample or PBS (control) and 0.8 ml of Tris-HCI (pH 8.5), and 
preincubated for 30 min at room temperature. Reaction was 
started by adding 0.05 ml of 4 mM substrate and change of ab- 
sorbance at 405 nm was monitored. Inhibitor activity was ex- 
pressed by the enzyme activity (nmol/min = unit) that was 
inhibited. 
Fibrin plate method was also used according to the method 
of Astrup and Miillertz [22] with modifications [14]. Urokinase 
(1.5 III/ml) was mixed with equal volume of inhibitor sample 
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Fig. I. SDS polyacrylamide gel electrophoresis of the purified 
epidermal PA1 (lane A) and molecular mass markers (lane B). 
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Fig.2. Effect of anti-PAI- and anti-PAI- antibodies on crude 
epidermal cell extract. The extract was incubated with PBS 
(*-_*), anti-PAI- (O---O), or anti-PAI- (m---m) for 30 min 
at 25°C before mixing with urokinase. Inhibitor assays were 
carried out using Glu-Gly-Arg-p-nitroanilide as substrate. 
or PBS (control) and the mixture (20~1) was placed on 
plasminogen-rich or plasminogen-free fibrin plates. 
In order to study neutralizing effects of antibodies on PA1 ac- 
tivity, each PA1 sample was incubated with equal volume of 
anti-PAI- IgG (0.2 mg/ml) or anti-PAI- IgG (0.5 mg/ml) for 
30 min at 25°C before starting inhibitor assays. 
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Fig.3. Effect of anti-PAI- and anti-PAI- antibodies on the 
reaction between urokinase and platelet PAI- (A---A), 
placental PAI- (O---O) and epidermal PA1 (M ). Inhibitor 
fractions were incubated with anti-PAI- (A) or anti-PAI- (B) 
for 30 min at 25°C and placed on plasminogen-rich fibrin 
plates. 
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15% sucrose, respectively, each overnight. Cryostat sections on 
albumin coated slides were air dried for 30 min and reacted with 
the primary IgG diluted (1: 100 to 1: 1000) with TPBS over- 
night. Sections were stained with ABC method using StrAvigen, 
according to the manufacturer’s instructions. Control studies 
were carried out using nonimmunized antiserum of each 
species, or by preabsorption of the antibody with cornified cell 
extract. 
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Fig.4. Immunoblots of purified epidermal PA1 (lane A) and 
partially purified placental PAL2 (lane B). After SDS- 
polyacrylamide gel electrophoresis, proteins were transferred 
and immunostained with ABC method by anti-PAI-I (left 
panel) or anti-PAI- (right panel). Small arrows indicate 
positions of molecular mass markers as in fig. 1. 
2.6. Immunohistochemical localization of PAI- and PAI- 
Human skins from healthy volunteers were fixed in 
periodate-lysine-paraformaldehyde [23]. Tissues were transfer- 
red to 0.1 M phosphate buffer, pH 7.2, containing 5, 10, and 
3. RESULTS 
3.1. Purification of epidermal PAI 
By the present procedures of purification an 
electrophoretically homogeneous protein with an 
A4, of 43000 was obtained (fig.1). Specific activity 
increased approx. 1500-fold from the starting ex- 
tracts with a yield of 6%, and the final product 
showed 20 unit/mg protein. 
3.2. Effect of anti-PAI- and anti-PAI- on PAI 
activities 
By the synthetic substrate assay, the crude 
(before purification) epidermal cell extract 
demonstrated linear dose-dependent inhibition for 
urokinase (fig.2). This inhibitor activity was com- 
pletely neutralized by anti-PAI- IgG, while it was 
not affected by anti-PAI-1. The neutralizing effect 
of anti-PAI-2, but not of anti-PAI-I , was confirm- 
ed with purified epidermal PAI, when inhibition of 
urokinase was measured by the fibrinolytic assay 
Fig.5. Immunohistochemical staining of normal human foot epidermis by monospecific antibodies against PAI- (left) or PAL2 
(right). Bars indicate 20 pm. 
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(fig.3). Control experiments with platelet PAI- 
and placental PAI- showed that anti-PAI- 
neutralized selectively the reactivity of PAI-1, 
while anti-PAI- neutralized selectively the reac- 
tivity of PAI- (fig.3), confirming previously 
reported results using the same antibodies [24]. 
3.3. Immunoblotting 
It was confirmed by SDS-polyacrylamide gel 
electrophoresis followed by immunoblotting that 
purified epidermal PAI, like placental PAI-2, 
reacted with anti-PAT-2 (fig.4). Neither epidermal 
PA1 nor placental PAI- showed immunoreactivi- 
ty to anti-PAI- 1, while control experiments show- 
ed that the same anti-PAI- antibody reacted in 
immunoblots with PAL1 [25]. 
3.4. Immunohistochemical localization of PAI- 
in human skin 
Human skin sections demonstrated im- 
munoreactivity to anti-PAI- IgG (fig.5). Cor- 
nified and granular cells were intensely stained 
while lower spinous cell layer showed reducing 
reactivity. Preabsorption of anti-PAI- IgG by the 
epidermal cell extract abolished the reactivity. On 
the other hand, there is some reactivity to anti- 
PAI- IgG, although PAI- activity was not detec- 
table (fig.2). 
4. DISCUSSION 
The purified epidermal PA1 was shown to be im- 
munologically related to PAI-2, since its inhibitory 
effect was neutralized by anti-PA13 and since it 
reacted with anti-PAZ-2 in immunoblots of SDS- 
polyacrylamide gels. The inhibitor did not 
crossreact with anti-PAI-1. Immunohistochemical 
analysis showed that PAZ-2 antigen is intensely 
localized in the granular and cornified cells. The 
pattern of localization of PAI- antigen accounts 
for that (1) the epidermal PAI- was extracted and 
purified from the cornified cells of foot epidermis, 
and (2) PA1 activity was stronger in the tissue ex- 
tract of uppermost layer of epidermis than whole 
epidermis (our unpublished data). Elevated PA ac- 
tivity has been demonstrated in (1) loss of in- 
tercellular coherence that results in bulla 
formation in pemphigus [15] and (2) accelerated 
turn-over of epidermal cells in psoriasis [ 161. 
Regulation of PA activity by the epidermal PAI- 
may be involved in prevention of such pathogenic 
conditions in the epidermis, and seems 
physiologically significant in the upper layer of 
normal epidermis where cell motility ceases. 
Monocytes/macrophages also contain PAI- 
[26,27], suggesting its extravascular role in con- 
trolling inflammation. Furthermore, im- 
munohistochemical analysis has shown that PAI- 
is present in trophoblastic epithelium of placenta 
P81. 
Although the inhibitor activity for urokinase by 
the epidermal extract was totally neutralized by 
anti-PAI- antibody but not by anti-PAI- an- 
tibody, the present immunohistochemistry showed 
a weak immunoreactivity to anti-PAI- remained 
in the human epidermis. The PAI-l-related antigen 
in the epidermal cells may not be present in the ex- 
tractable condition, or may be functionally in- 
active. 
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